Niagen Bioscience (NAGE) said Monday that it does not expect global tariffs to disrupt its ability to manufacture food- and pharmaceutical-grade Niagen products, nor will they have an adverse impact on its ability to maintain costs and pricing.
The company said all of its vitamins and food supplements are manufactured in the US by privately held specialty chemicals company WR Grace and are tested, bottled and packaged domestically. It also said only a small percentage of its raw materials are sourced internationally, which keeps costs relatively stable in the face of global price volatility.
Foreign sales accounted for 24% of Niagen's revenue last year, with half of that coming from AS Watson in Hong Kong, which remains a duty-free market, the company said.
Niagen chief executive officer Rob Fried said the company had previously decided to establish a US-based supply chain to ensure long-term resilience and quality.
Niagen shares were more than 6% lower soon after Monday's opening bell.
Price: 5.64, Change: -0.38, Percent Change: -6.23
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.